BSMS > About BSMS > Contact us > Staff > Dr Eleni Ladikou

Dr Eleni Ladikou

Clinical PhD Fellowship
E: eleni.ladikou@nhs.net
Location: Write-up room 2, Medical Research Building, University of Sussex, BRIGHTON, BN1 9PX

PA: Gemma Hamilton
E: G.Hamilton@bsms.ac.uk
Tel: + 44 (0)1273 877662

Areas of expertise: Haematology

Research areas: Bone Marrow microenvironment in Acute Myeloid Leukaemia

Preferred gender pronouns: she/her

Twitter handle: @EleniLadikou

Biography

At a very early stage in Eleni's medical training, she committed to a career in clinical academia where she can intermix the rewards of human interaction in clinical medicine with her passion for medical research. Eleni is now a PhD Clinical Fellow investigating the role of Bone Marrow microenvironment in Acute Myeloid Leukaemia. She also works part-time as a clinical trial sub-investigator testing Janssen COVID-19 Vaccine (Johnson & Johnson). She is passionate about academic haematology and translational research. Eleni has successfully completed Core Medical Training, Academic Clinical Fellowship in Haematology and Academic Foundation Programme. Her short-term goal from her PhD research project is to gain more experience in fundamental scientific research and laboratory techniques, learn from field experts and get involved in innovative, high quality medical research. In the long-term, she is committed to developing the skills needed to be a successful academic clinical lecturer and accomplished academic haematologist.

Research

For the last 3 years, Eleni has worked on Acute Myeloid Leukaemia (AML), which is still a big clinical challenge with poor prognosis and high relapse rate. Her interaction with AML patients in clinic has motivated her even further to pursue a PhD in this exciting field, particularly investigating the role of the bone marrow microenvironment in AML, which contributes to disease relapse. Eleni has particularly enjoyed working on the development of a model of the AML microenvironment and believes that this is the right project for her at BSMS. This project is supervised as an amalgamation of expertise between Professor Chris Pepper and Dr Andrea Pepper, who are internationally renowned scientists with years of experience in modelling the microenvironment in leukaemia biology, and Dr Tim Chevassut, who is an experienced AML clinical academic.

Selected publications

*Ladikou EE, Sivaloganathan H, Pepper AG, Chevassut T. AML in its niche - the Bone Marrow microenvironment in Acute Myeloid Leukemia. Curr Oncol Rep 2020 Feb 11; 22(3):27.

*Ladikou EE, Chevassut T, Pepper C, Pepper AG. Dissecting the role of the CXCL12/CXCR4 axis in Acute Myeloid Leukaemia. Brit. Journal of Haematology 2020 Jun; 189(5):815-825.3.

Ladikou EE, Sivaloganathan H, Milne K, Arter W, Ramasamy R, Saad R, Stoneham S, Philips B, Eziefula A, Chevassut T. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19? Clin Med (Lond) 2020 2020 Sep; 20(5):e178-e1824.

Ladikou EE*, Sivaloganathan H*, Chevassut T. COVID-19 mortality in patients on anticoagulants and antiplatelet agents. Brit. Journal of Haematology 2020 Aug; 190(4):e192-e195.5.

Stoneham S, Milne K, Nuttall E, Frew G, Sturrock B, Sivaloganathan H, Ladikou EE, Drage S, Phillips B, Chevassut T, Eziefula A. Thrombotic risk in COVID-19: a case series and case-control study. Clin Med (Lond) 2020 Jul; 20(4):e76-e81.6.

Ladikou, E.; Ottolini, B.; Nawaz, N.; Allchin, R.L.; Payne, D.; Ali, H.; Marafioti, T.; Shaw, J.; Ahearne, M.J.; Wagner, S.D. Clonal evolution in the transition from cutaneous disease to acute leukaemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm. Haematologica 2018,103, e196–e199 7.

Byford ET, Carr M, Ladikou E, Ahearne MJ, Wagner SD. CirculatingTfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin’s lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma. PLoS ONE 2018 Jan 2; 13(1):e01904688.

Ladikou EE, Kassi E. The emerging role of oestrogen in B cell malignancies. Leukemia & lymphoma 2017 58 (3), 528-539